Inovio Pharmaceuticals Inc INO

Healthcare Biotechnology

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

NDAQ:INO - Post by User

Inovio Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by 7Twiggyon Feb 04, 2021 4:49pm

127 Views

Post# 32478707

Should one add at these levels?

Wondering if I should add. Stock has dropped for the last few sessions, but if INO -4800 is
successful it will make the moves Moderna has made in the last few days look small. I got out of
Moderna at $40.00, so am not going to pull the trigger on this one anytime soon.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023